PMFA
SRPT icon

Plante Moran Financial Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Plante Moran Financial Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$270 Buy
+15
New +$284 ﹤0.01% 1344
2022
Q1 		– Sell
-20
Closed -$2K – 993
2021
Q4 		$2K Buy
+20
New +$1.71K ﹤0.01% 928

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Plante Moran Financial Advisors's SRPT Position: Q2 2026 in Review

Plante Moran Financial Advisors opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 15 shares worth $270. The stake represents ﹤0.01% of the portfolio and ranks #1344 among its holdings. This is a return to the name: Plante Moran Financial Advisors previously reported a position in SRPT as recently as Q4 2021.

Plante Moran Financial Advisors first reported a position in SRPT in Q4 2021 and has held it in 2 quarters since. The position peaked at $2K in Q4 2021. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Plante Moran Financial Advisors held 15 shares of Sarepta Therapeutics worth $270 as of Q2 2026.
  • Sarepta Therapeutics was a new Plante Moran Financial Advisors position in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Plante Moran Financial Advisors's portfolio in Q2 2026, its #1344 holding.
  • Plante Moran Financial Advisors first reported a position in Sarepta Therapeutics in Q4 2021 and has held it in 2 quarters since.
  • Plante Moran Financial Advisors's Sarepta Therapeutics position peaked at $2K in Q4 2021.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Plante Moran Financial Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.